Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Debt to Equity (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Debt to Equity data on record, last reported at -$1.23 in Q3 2025.

  • For Q3 2025, Debt to Equity fell 0.62% year-over-year to -$1.23; the TTM value through Sep 2025 reached -$1.23, down 0.62%, while the annual FY2024 figure was -$1.1, 38.15% up from the prior year.
  • Debt to Equity reached -$1.23 in Q3 2025 per BTAI's latest filing, down from -$1.01 in the prior quarter.
  • Across five years, Debt to Equity topped out at $16.66 in Q2 2023 and bottomed at -$2.46 in Q3 2023.
  • Average Debt to Equity over 4 years is $0.53, with a median of -$1.1 recorded in 2024.
  • The widest YoY moves for Debt to Equity: up 623751.42% in 2023, down 439.44% in 2023.
  • A 4-year view of Debt to Equity shows it stood at $1.22 in 2022, then tumbled by 246.22% to -$1.78 in 2023, then skyrocketed by 38.15% to -$1.1 in 2024, then dropped by 11.46% to -$1.23 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were -$1.23 in Q3 2025, -$1.01 in Q2 2025, and -$1.17 in Q1 2025.